[Event Report] The First Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC) (January 22, 2020)
date : 2/11/2020
Tags: AMR
![[Event Report] The First Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC) (January 22, 2020)](https://hgpi.org/en/wp-content/uploads/sites/2/AMIC-top.jpg)
Nikkei Inc. and AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) jointly held the First Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC).
At this first sub-committee, participants from academia, the Government, industry and civil society discussed potential policy options to ensure sustainable research and development (R&D) for antimicrobials.
Participants agreed to continue to discuss the state of the antimicrobial market in working groups toward the eventual formulation of a concrete proposal on ways to incentivize antimicrobial R&D in the future.
■Overview
Date and time: Wednesday, January 22, 2020
Organizer: AMR Alliance Japan (Secretariat: HGPI)
■Program
The role of the AMR sub-committee
Mitsuru Miyata (Adviser, Medical and Healthcare Division, Nikkei Business Publications, Inc.)
Shigeru Omi (President, Japan Community Health care Organization (JCHO) / Regional Director Emeritus, Regional Office for the Western Pacific (WPRO), World Health Organization (WHO))
AMR Alliance Japan
Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute (AMR Alliance Japan Secretariat))
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Discussion —Policy options to revitalize the antimicrobial industry
From the perspective of the Cabinet Secretariat:
Hiroyuki Noda (Councilor, Coordination Office of Measures on Emerging Infectious Diseases, Office of Pandemic Influenza and New Infectious Diseases Preparedness and Response, Cabinet Secretariat)
From the perspective of the Ministry of Health, Labour and Welfare:
Manami Yanagawa (Chief, Tuberculosis and Infectious Diseases Control Division, Ministry of Health, Labour and Welfare (MHLW))
From the perspective of the pharmaceutical industry
Takeo Morooka (Executive Officer, Head of Health Policy and Corporate Support, MSD K.K.) Takuko Sawada (Executive Vice President, Shionogi & Co., Ltd.)
Chairs:
Shigeru Omi (President, Japan Community Health care Organization (JCHO) / Regional Director Emeritus, Regional Office for the Western Pacific (WPRO), World Health Organization (WHO))
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Facilitator:
Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute (AMR Alliance Japan Secretariat))
Top Research & Recommendations Posts
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Policy Recommendations] Reshaping Japan’s Immunization Policy for Life Course Coverage and Vaccine Equity: Challenges and Prospects for an Era of Prevention and Health Promotion (April 25, 2025)
- [Policy Recommendations] Strengthening Lifelong Mental Health Support for Children with Intellectual Disabilities (April 30, 2025)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Event Report] Round Table Discussion “Understanding Menopausal Women’s Health as a Social Issue” (Preliminary Version) (November 19, 2024)
- [Recommendations] HGPI Expert Policy Advocacy Platform “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 7, 2025)
- [Policy Recommendations] Achieving a Sustainable Society of Health and Longevity Through the Integration of Environment and Healthcare-Incorporating a Planetary Health Perspective into the 3rd Phase of The Healthcare Policy-(December 20, 2024)
Featured Posts
-
2025-04-17
[Registration Open] (Webinar) The 134th HGPI Seminar “Understanding Evidence-Based Dietary Guidelines: Leveraging the Dietary Reference Intakes for Japanese” (May 28, 2025)
-
2025-04-23
[Registration Open] Recruitment of the Health Policy Academy the 14th Session (Starts July 2025)
-
2025-05-02
[Registration Open] (Webinar) The 133rd HGPI Seminar -HGPI Expert Policy Advocacy Platform- “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 20, 2025)
-
2025-05-07
[Recommendations] HGPI Expert Policy Advocacy Platform “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 7, 2025)
-
2025-05-07
[Registration Open] Japan-Australia Online Round Table Discussion “The Impact of Social Media on the Mental Health of Children and Young People and How Social Media Should Be Used in Society“ (May 23, 2025)